Biochemical effects of a quinazoline inhibitor of thymidylate synthetase, N-(4-(N-(( 2-amino-4-hydroxy-6-quinazolinyl)methyl)prop-2-ynylamino) benzoyl)-L-glutamic acid (CB3717), on human lymphoblastoid cells.

No abstract is available for this paper.

• Publication year

  1983

• Venue

  Biochemical Pharmacology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/0006-2952(83)90150-8PMID 6661252
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A potent antitumour quinazoline inhibitor of thymidylate synthetase: synthesis, biological properties and therapeutic results in mice.

  1981cited by this paper
• Antifolate-induced misincorporation of deoxyuridine monophosphate into DNA: inhibition of high molecular weight DNA synthesis in human lymphoblastoid cells.

  1981cited by this paper
• Quinazoline antifolates with dual biochemical loci of action. Biochemical and biological studies directed towards overcoming methotrexate resistance.

  1980cited by this paper
• Isolation of a homogeneous preparation of human thymidylate synthetase from HeLa cells.

  1980cited by this paper
• Methotrexate-induced misincorporation of uracil into DNA.

  1980cited by this paper
• Purine and pyrimidine nucleotide patterns of normal, differentiating, and regenerating liver and of hepatomas in rats.

  1980cited by this paper
• 5-substituted quinazoline antifolates.

  1980cited by this paper
• The effect of methotrexate on levels of dUTP in animal cells.

  1980cited by this paper
• Modulation of methotrexate toxicity by thymidine: sequence-dependent biochemical effects.

  1980cited by this paper
• Kinetic simulation of anticancer drug interactions.

  1980cited by this paper
• Role of thymidylate synthetase activity in development of methotrexate cytotoxicity.

  1979cited by this paper
• Effects of nucleoside triphosphates on human ribonucleotide reductase from Molt-4F cells.

  1979cited by this paper
• Enzyme pattern-directed chemotherapy. Effects of antipyrimidine combinations on the ribonucleotide content of hepatomas.

  1979cited by this paper
• Effect of 5-fluorouracil on RNA metabolism in Novikoff hepatoma cells.

  1979cited by this paper
• Quinazolines as inhibitors of dihydrofolate reductase. 4. Classical analogues of folic and isofolic acids.

  1977cited by this paper
• Acquired methotrexate resistance in lymphoblasts resulting from altered kinetic properties of dihydrofoltate reductase.

  1977cited by this paper
• Reactivation of dihydrofolate reductase inhibted by methotrexate or aminopterin.

  1977cited by this paper
• Intrinsic resistance to methotrexate of cultured mammalian cells in relation to the inhibition kinetics of their dihydrololate reductases.

  1976cited by this paper
• Adenosine metabolism in cultured lymphoid cells.

  1976cited by this paper
• Factors determining cell sensitivity to methotrexate: studies of folate and deoxyribonucleoside triphosphate pools in five mammalian cell lines.

  1974cited by this paper
• Inhibition of ribosomal ribonucleic acid maturation in Novikoff hepatoma cells by 5-fluorouracil and 5-fluorouridine.

  1973cited by this paper
• Combination chemotherapy: the interaction of methotrexate and 5-fluorouracil.

  1973cited by this paper
• Mycoplasma contamination of animal cell cultures: a simple, rapid detection method.

  1972cited by this paper
• Purineless death as a link between growth rate and cytotoxicity by methotrexate.

  1972cited by this paper
• ACTIVE‐SITE DIRECTED IRREVERSIBLE INHIBITORS OF DIHYDROFOLATE REDUCTASE *

  1971cited by this paper
• SITES OF ACTION OF AMETHOPTERIN: INTRINSIC AND ACQUIRED DRUG RESISTANCE *

  1971cited by this paper
• A method for the determination of dATP and dTTP in picomole amounts.

  1970cited by this paper
• 2-amino-4-hydroxyquinazolines as inhibitors of thymidylate synthetase.

  1970cited by this paper
• Studies relating to the mode of action of methotrexate. 3. Inhibition of thymidylate synthetase in tissue culture cells and in cell-free systems.

  1969cited by this paper
• A rapid quantitative determination of deoxyribonucleoside triphosphates based on the enzymatic synthesis of DNA.

  1969cited by this paper
• Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors.

  1969cited by this paper
• Stimulatory effects of inosine and deoxyinosine on the incorporation of uracil-2-14-C, 5-fluorouracil-2-14-C, and 5-bromouracil-2-14-C into nucleic acids by Ehrlich ascites tumor cells in vitro.

  1969cited by this paper
• Studies relating to the mode of action of methotrexate. II. Studies on sites of action in L-cells in vitro.

  1969cited by this paper
• Human lymphoblastoid lines from lymph node and spleen

  1968cited by this paper
• THE INFLUENCE OF CYTOSTATIC TREATMENT ON SERUM LDH PATTERNS OF PATIENTS WITH BRONCHIAL CARCINOMA AND ITS RELATION TO TUMOR REGRESSION

  1968cited by this paper
• Regulation of mammalian deoxyribonucleotide biosynthesis by nucleotides as activators and inhibitors.

  1966cited by this paper
• An isotopic assay for thymidylate synthetase.

  1966cited by this paper

• Bioisoteres for carboxylic acids: From ionized isosteres to novel unionized replacements.

  2024cites this paper
• Acetylenic antifolates as anticancer agents

  2015cites this paper
• A novel thiazolidine compound induces caspase-9 dependent apoptosis in cancer cells.

  2012cites this paper
• Thiothymidine combined with UVA as a potential novel therapy for bladder cancer

  2011cites this paper
• Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications

  2007cites this paper
• Quinazoline Antifolate Thymidylate Synthase Inhibitor That Is a Potent Inhibitor of LI 210 Tumor Cell Growth in Vitro and in Vivo : A New Agent for Clinical Study 1

  2006cites this paper
• Dipyridamole Damage , and Growth Inhibition following Exposure to CB 3717-triphosphate Accumulation , DNA ′-Deoxyuridine-5 ′ Inhibition : 2 Mechanism of Cell Death following Thymidylate Synthase Updated

  2006cites this paper
• From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates

  2006cites this paper
• Thymidylate synthase inhibitors.

  2006cites this paper
• Computer modelling of antifolate inhibition of folate metabolism using hybrid functional petri nets.

  2006cites this paper
• Novel chemical strategies for thymidylate synthase inhibition.

  2005cites this paper
• Amplification of the thymidylate synthase gene in anN10-propargyl-5,8-dideazafolic-acid-resistant human leukemia, MOLT-3 cell line developed in pteroylglutamic acid, but not in leucovorin

  2005cites this paper
• The role of folates in the development of methotrexate resistance in human leukemia cell line K562

  2005cites this paper
• A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies

  2004cites this paper
• Biological and biochemical properties of new anticancer folate antagonists

  2004cites this paper
• The clinical pharmacokinetics of the novel antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717)

  2004cites this paper
• The pharmacokinetics of the quinazoline antifolate ICID 1694 in mice and rats

  2004cites this paper
• TomudexTM (ZD1694): from concept to care, a programme in rational drug discovery

  2004cites this paper
• A Mathematical Model of the Folate Cycle

  2004cites this paper
• Polymorphism in the thymidylate synthase promoter enhancer region modifies the risk and survival of colorectal cancer.

  2003cites this paper
• Anticancer antifolates: current status and future directions.

  2003cites this paper
• Antifolate chemistry: synthesis of 4-[N-[(6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl]-N-(prop-2-ynyl)amino]benzoic acid via a (propargyl)Co2(CO)6+ complex.

  2003cites this paper
• Synthesis and in vitro antitumor activity of thiophene analogues of 5-chloro-5,8-dideazafolic acid and 2-methyl-2-desamino-5-chloro-5,8-dideazafolic acid.

  2002cites this paper
• Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331.

  2002cites this paper
• Pemetrexed disodium, a novel antifolate with multiple targets.

  2001cites this paper
• The ability to accumulate deoxyuridine triphosphate and cellular response to thymidylate synthase (TS) inhibition

  2001cites this paper
• Multi-targeted antifolates aimed at avoiding drug resistance form covalent closed inhibitory complexes with human and Escherichia coli thymidylate synthases.

  2001cites this paper
• Approaches to solving the rigid receptor problem by identifying a minimal set of flexible residues during ligand docking.

  2001cites this paper
• Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations.

  2001cites this paper
• Modified high-performance liquid chromatography assay for the measurement of 2'-deoxyuridine in human plasma and its application to pharmacodynamic studies of antimetabolite drugs.

  2000cites this paper
• Deoxyuridine triphosphatase (dUTPase) expression and sensitivity to the thymidylate synthase (TS) inhibitorD9331

  2000cites this paper
• The crystal structure of thymidylate synthase from Pneumocystis carinii reveals a fungal insert important for drug design.

  2000cites this paper
• Design and synthesis of Cyclopenta[g]quinazoline-based antifolates as inhibitors of thymidylate synthase and potential antitumor agents(,).

  2000cites this paper
• Thymidylate synthase inhibitors.

  1999cites this paper
• Antifolate Drugs in Cancer Therapy

  1999cites this paper
• An overview of folate metabolism: features relevant to the action and toxicities of antifolate anticancer agents.

  1999cites this paper
• The additivity of substrate fragments in enzyme-ligand binding.

  1998cites this paper
• Nonpolyglutamatable antifolates as inhibitors of thymidylate synthase (TS) and potential antitumour agents.

  1998cites this paper
• Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.

  1998cites this paper
• Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase.

  1997cites this paper
• Folate-based thymidylate synthase inhibitors in cancer chemotherapy.

  1997cites this paper
• Cellular and molecular mechanisms of resistance to antifolate drugs: new analogues and approaches to overcome the resistance.

  1997cites this paper
• The effects of combined antifolates on inhibition of growth of murine leukemia cells cultured in vitro.

  1997cites this paper
• Cytotoxicity of Trimetrexate against Antifolate‐resistant Human T‐Cell Leukemia Cell Lines Developed in Oxidized or Reduced Folate

  1997cites this paper
• Cellular responses to antimetabolite anticancer agents: cytostasis versus cytotoxicity.

  1996cites this paper
• Immunoreactive dUMP and TTP pools as an index of thymidylate synthase inhibition; effect of tomudex (ZD1694) and a nonpolyglutamated quinazoline antifolate (CB30900) in L1210 mouse leukaemia cells.

  1996cites this paper
• Thymidylate synthase inhibitors.

  1996cites this paper
• Binding of the anticancer drug ZD1694 to E. coli thymidylate synthase: assessing specificity and affinity.

  1996cites this paper
• The complex of the anti-cancer therapeutic, BW1843U89, with thymidylate synthase at 2.0 A resolution: implications for a new mode of inhibition.

  1996cites this paper
• Phase I trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion.

  1996cites this paper
• Mechanisms of clinical resistance to 5-fluorouracil chemotherapy.

  1996cites this paper
• Antifolates: current developments.

  1996cites this paper
• Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma.

  1996cites this paper
• Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3,4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridplthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous intravenous infusion

  1995cites this paper
• Folate-based thymidylate synthase inhibitors as anticancer drugs.

  1995cites this paper
• Initiatives with platinum- and quinazoline-based antitumor molecules--Fourteenth Bruce F. Cain Memorial Award Lecture.

  1995cites this paper
• Quinazoline thymidylate synthase inhibitors: methods for assessing the contribution of polyglutamation to their in vitro activity.

  1995cites this paper
• 5,10-Dideazatetrahydrofolic acid reduces toxicity and deoxyadenosine triphosphate pool, expansion in cultured L1210 cells treated with inhibitors of thymidylate synthase.

  1995cites this paper
• Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3, 4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous intravenous infusion.

  1995cites this paper
• The synthesis and thymidylate synthase inhibitory activity of L-gamma-L-linked dipeptide and L-gamma-amide analogues of 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583).

  1994cites this paper
• Modulation of target enzyme associated with the action of antifolates.

  1994cites this paper
• The in vivo metabolic stability of dipeptide analogues of the quinazoline antifolate, ICI 198583, in mice.

  1993cites this paper
• Antineoplastic Drug Resistance and Breast Cancer

  1993cites this paper
• Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase.

  1993cites this paper
• Enhanced cytotoxicity of 5-fluorouracil combined with [6RS]leucovorin and recombinant human interferon-alpha 2a in colon carcinoma cells.

  1993cites this paper
• Synthesis and antifolate evaluation of the 10-propargyl derivatives of 5-deazafolic acid, 5-deazaaminopterin, and 5-methyl-5-deazaaminopterin.

  1992cites this paper
• Time dependence of DNA lesions and growth inhibition by ICI D1694, a new quinazoline antifolate thymidylate synthase inhibitor.

  1992cites this paper
• Variations in patterns of DNA damage induced in human colorectal tumor cells by 5-fluorodeoxyuridine: implications for mechanisms of resistance and cytotoxicity.

  1992cites this paper
• N10-propargyl-5,8-dideazafolic acid (CB3717): inhibitory effects on human leukemia cell lines resistant to methotrexate or trimetrexate.

  1992cites this paper
• Syntheses and thymidylate synthase inhibitory activity of the poly-gamma-glutamyl conjugates of N-[5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino ]-2-thenoyl]-L-glutamic acid (ICI D1694) and other quinazoline antifolates.

  1992cites this paper
• Quinoline antifolate thymidylate synthase inhibitors: variation of the C2- and C4-substituents.

  1992cites this paper
• Organ culture as a model for investigating the effects of antimetabolites and nucleoside transport inhibitors on rodent colonic mucosa

  1991cites this paper
• Interaction between 5-fluorouracil, [6RS]leucovorin, and recombinant human interferon-alpha 2a in cultured colon adenocarcinoma cells.

  1991cites this paper
• Mechanism of cell death following thymidylate synthase inhibition: 2'-deoxyuridine-5'-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole.

  1991cites this paper
• Design of enzyme inhibitors using iterative protein crystallographic analysis.

  1991cites this paper
• Quinazoline antifolates inhibiting thymidylate synthase: 4-thio-substituted analogues.

  1991cites this paper
• The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583).

  1991cites this paper
• Quinazoline antifolate thymidylate synthase inhibitors: bridge modifications and conformationally restricted analogues in the C2-methyl series.

  1991cites this paper
• Folate antimetabolites inhibitory to de novo purine synthesis.

  1991cites this paper
• Thymidylate synthase inhibitors: the in vitro activity of a series of heterocyclic benzoyl ring modified 2-desamino-2-methyl-N10-substituted-5,8-dideazafolates.

  1991cites this paper
• ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study.

  1991cites this paper
• Structure, multiple site binding, and segmental accommodation in thymidylate synthase on binding dUMP and an anti-folate.

  1990cites this paper
• Mechanism of thymidylate synthase inhibition by methotrexate in human neoplastic cell lines and normal human myeloid progenitor cells.

  1990cites this paper
• Cytotoxic synergism between trimetrexate and etoposide. Evidence that trimetrexate potentiates etoposide-induced protein-associated DNA strand breaks in L1210 leukemia cells through alterations in intracellular ATP concentrations.

  1990cites this paper
• Role of substrate depletion in the inhibition of thymidylate biosynthesis by the dihydrofolate reductase inhibitor trimetrexate in cultured hepatoma cells.

  1990cites this paper
• Quinazoline folate analogs inhibit the catalytic activity of thymidylate synthase but allow binding of 5-fluorodeoxyuridylate.

  1990cites this paper
• Activity of the thymidylate synthase inhibitor 2-desamino-N10-propargyl-5,8-dideazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in L1210 in vivo.

  1990cites this paper
• Quinazoline antifolate thymidylate synthase inhibitors: 2'-fluoro-N10-propargyl-5,8-dideazafolic acid and derivatives with modifications in the C2 position.

  1990cites this paper
• Synchronisation of cancer cell lines of human origin using methotrexate.

  1990cites this paper
• Potent inhibitors of de novo pyrimidine and purine biosynthesis as chemotherapeutic agents

  1990cites this paper
• Thymidylate synthase: a target for anticancer drug design.

  1989cites this paper
• (6R,6S)-5,8,10-trideaza-5,6,7,8-tetrahydrofolate and 6(R,6S)-5,8,10-trideaza-5,6,7,8-tetrahydropteroyl-L-ornithine as potential antifolates and antitumor agents.

  1989cites this paper
• Chemistry and biological activity of antifolates.

  1989cites this paper
• The quantitation by radioimmunoassay of 2'-deoxyuridine 5'-triphosphate in extracts of thymidylate synthase-inhibited cells.

  1989cites this paper
• Metabolism of new anticancer agents.

  1989cites this paper
• Quinazoline antifolates inhibiting thymidylate synthase: 2-desamino derivatives with enhanced solubility and potency.

  1989cites this paper
• A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis.

  1989cites this paper
• Quinazoline antifolate thymidylate synthase inhibitors: nitrogen, oxygen, sulfur, and chlorine substituents in the C2 position.

  1989cites this paper
• The role of cellular folates in the enhancement of activity of the thymidylate synthase inhibitor 10-propargyl-5,8-dideazafolate against hepatoma cells in vitro by inhibitors of dihydrofolate reductase.

  1989cites this paper
• Modulation of dipyridamole action by alpha 1 acid glycoprotein. Reduced potentiation of quinazoline antifolate (CB3717) cytotoxicity by dipyridamole.

  1989cites this paper